OBJECTIVE: A general vaccination of newborns with PnC-7 reduces pneumococcal diseases and also the rate of pneumococcal diseases in unvaccinated adults (herd immunity). Usually cohort of patients followed subsequent cycles in a Markov model. In this study, age and class were computed cross sectionally. The objective of this study was to evaluate the annual health outcomes and cost-effectiveness of a general vaccination with PnC-7 in a hypothetical steady state German cohort across all age groups with base year 2003 focusing health care payers' perspective. METHODS: The efficacies of PnC-7 and herd immunity were adjusted to serotype distribution according to two German panels. The model included incidences of pneumococcal diseases, fatality rates, rate of long-term sequelae, age specific German population structure, 3 + 1 application of PnC-7, and health care expenditures for treatment of pneumococcal diseases. Critical key data were varied in a sensitivity analysis. RESULTS: A vaccination rate PnC-7 of 68% is able to avoid 4256 invasive pneumococcal diseases, 57,727 pneumococcal pneumonias, 274,332 cases of otitis media, 99 longterm sequelaes and 2257 deaths resulting in 34,237 life years gained in Germany every year. From health care payer's view the cost savings outweighed the vaccination administration with factor 1.23 and costs of a life-year-saved are 887€. The one-way sensitivity analysis showed the estimations were sensitive to reduction in incidence of otitis media and health care costs, but the vaccination with PnC-7 remained cost saving. On the other hand, the incorporation of an ageing German population, 2 + 1 application of PnC-7, herd immunity without serotype adjustments or non-discounting of life year gained resulted in conservative costeffectiveness estimations. CONCLUSIONS: From the German health care payer view, a general vaccination with conjugate vaccine PnC-7 is cost saving.
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PIH2 THE COST-EFFECTIVENESS OF EXPANDING NEWBORN SCREENING FOR INHERITED METABOLIC DISORDERS USING TANDEM MASS SPECTROMETRY
Cipriano LE, Rupar CA, Zaric GS University of Western Ontario, London, ON, Canada OBJECTIVES: Currently, newborns in Ontario, Canada, are screened for phenylketonuria (PKU) using the Guthrie method. Tandem mass spectrometry (MS/MS) can allow several other metabolic diseases to be screened for at birth. We estimated the costs, health benefits, and cost-effectiveness of using MS/MS to expand the newborn screening program in Ontario to include 20 additional metabolic diseases. METHODS: We constructed a decision-analytic model to estimate the incremental costs and life years of survival gained associated with screening by MS/MS versus the status quo (either not screening or screening with a different technology). Disease prevalence, test characteristics, treatment effectiveness, disease progression rates, and mortality were estimated from secondary sources and expert opinion. Costs were estimated primarily from the London Health Sciences Center Case Costing Initiative, the Ontario Health Insurance Plan Schedule of Benefits, and the Ontario Drug Benefits Plan formulary. Costs and health benefits were estimated for a cohort of babies born in Ontario in one year. RESULTS: Using MS/MS to screen for PKU has an incremental cost of $2,800,000 per life year (LY) gained. When each additional disease was evaluated independently, the cost of screening with MS/MS ranged from cost-saving to $158,000/LY gained. Using MS/MS to screen for PKU and 16 additional diseases costs $17,100/LY gained. CON-CLUSIONS: Newborn screening reduces morbidity, mortality, and the social burden of irreversible effects of disease on the population. The severity and onset of disease symptoms can be prevented through early diagnosis and treatment. Our analysis suggests that screening for PKU and 16 additional diseases has an incremental cost effectiveness ratio below $50,000/LY gained. However, it is not cost effective to screen for all diseases that can be tested for using MS/MS. Janssen Medical Affairs, Grayslake, IL, USA; 2 Janssen Medical Affairs, Titusville, NJ, USA OBJECTIVE: To compare direct costs of treatment of children (ages 3-17) with a diagnosis of an autism spectrum disorder (autism) to a group of children having either a diagnosis of diabetes or asthma. METHODS: This was a retrospective, claimsbased study of children enrolled in the California Medicaid (Medi-Cal) program from 1996-2002. Direct treatment costs were based on utilization of inpatient, outpatient, pharmacy, and ancillary services for all Medi-Cal eligible patients, starting six-months prior to a diagnosis of autism, diabetes, or asthma (index date) to 12-months following a diagnosis. Medical and prescription claims were categorized by psychiatric and nonpsychiatric services. Health care costs for autistic children were then compared to costs from the randomly selected, gender matched, cohorts of children with diabetes or asthma. Descriptive statistics on demographics and non-parametric statistics on costs (Kruskal-Wallis) were performed. RESULTS: The average age of children with autism (n = 731) was 8.6 ± 4.0 years, compared with diabetes (n = 731) 12.1 ± 4.3 years, and asthma (n = 731) 6.3 ± 3.0 years. A total of 75.4% of subjects were male. Majority (37.1%) of the autism sample was White, while majority of the asthma and diabetes children were Hispanic (44.1% and 40.0%, respectively). Total median health care costs were significantly different among disease groups. Children with autism had higher annual costs (pre-diagnosis: $363; post: $1199) than children with diabetes (pre: $171; post: $649) or asthma (pre: $147; post: $424) (all P < 0.0001). Psychiatric and non-psychiatric cost categories were statistically significant. Additionally, the period prevalence for autism in this population increased 114% over the study period, compared to a 42% decrease in asthma and a 3% decrease in diabetes. CONCLU-SIONS: This study estimates that autistic children incur greater health care costs than children with diabetes or asthma. These findings reflect the significant cost of illness for autism relative to other chronic pediatric conditions in this Medi-Cal population.
PIH4 THE QUALITY OF COMMUNITY PEDIATRICIAN'S PRESCRIPTIONS
Triki N, Cohen R, Raz M Maccabi Healthcare Services, Rishon Le Zion, Israel There are several reasons why prescriptions for children's medications may have more mistakes than those for adults' medications: dosage is adjusted to weight rather than being constant,
